MutL Homolog 21 as A Cancer Drug Target and Biomarker (G219927)

Target Name: MRPL21

NCBI ID: G219927

MRPL21

MutL Homolog 21 as A Cancer Drug Target and Biomarker

MRPL21 (MutL homolog 21) is a gene that encodes a protein known as MRPL21. MutL homolog 21 is a non-coding RNA molecule that plays a role in regulating microRNA (miRNA) levels in various organisms. The most well-known function of MutL homolog 21 is that it functions as a negative regulator of the miRNA-protein interaction, which is critical for proper cellular processes.

Recent studies have identified MutL homolog 21 as a potential drug target and biomarker for various diseases, including cancer. This is because the dysfunction of MutL homolog 21 has been implicated in the development and progression of several diseases, including cancer.

One of the key reasons for the potential of MutL homolog 21 as a drug target is its involvement in the regulation of miRNA levels. MiRNA is a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation by binding to specific target genes and affecting their stability. MutL homolog 21 has been shown to function as a negative regulator of miRNA levels, which means that it tends to keep miRNA levels low.

In cancer, MutL homolog 21 is often overexpressed or mutated, which can lead to the dysregulation of miRNA levels and contribute to the development and progression of cancer. For example, studies have shown that MutL homolog 21 is often overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, mutations in MutL homolog 21 have been implicated in the development of certain cancers, including lung cancer.

Another potential mechanism by which MutL homolog 21 may contribute to cancer development is its role in cell signaling pathways. MutL homolog 21 has been shown to play a role in the regulation of various signaling pathways, including the TGF-β pathway. TGF-β is a critical signaling pathway that regulates cell growth, differentiation, and survival, and is involved in the development and progression of many diseases, including cancer.

In addition to its role in cell signaling pathways, MutL homolog 21 may also contribute to cancer development by regulating the expression of genes involved in cell adhesion and migration. MutL homolog 21 has been shown to play a role in the regulation of genes involved in cell adhesion and migration, including the E-cadherin gene. E-cadherin is a transmembrane protein that is involved in cell adhesion and has been implicated in the development and progression of many diseases, including cancer.

Finally, MutL homolog 21 may also contribute to cancer development by regulating the expression of genes involved in cell survival and angiogenesis. Cell survival and angiogenesis are critical processes that are involved in the development and progression of cancer, and MutL homolog 21 has been shown to play a role in regulating the expression of genes involved in these processes.

In conclusion, MutL homolog 21 is a gene that has been implicated in the development and progression of many diseases, including cancer. Its function as a negative regulator of miRNA levels and its involvement in various signaling pathways and cell processes make it an attractive drug target and biomarker for cancer treatment. Further research is needed to fully understand the role of MutL homolog 21 in cancer development and to develop effective treatments.

Protein Name: Mitochondrial Ribosomal Protein L21

The "MRPL21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets